Explore opportunities
Search by company name (Bolden, Pax, OncoLux, Nabsys), asset id, or title. Each card links to a full dossier with cited evidence.
Loading filters…
DARPA-scale wireless neurograins—dense cortical sensing without Utah-array tethers.
Brown OTL spinout after ~$19M DARPA + UH2—hardware path parallel to BrainGate decode IP.
Recruiting speech and tablet iBCI trials—decode IP distinct from electrode vendors.
U01 + VA funding with NCT05724173 family—consortium license or device co-development.
Open dossierHospital-owned non-viral RNA nanocarriers—STTR-backed with expanded field-of-use option.
RIH assignee + R41TR002298—license to NanoDe or second newco beyond current scope.
Open dossierChitinase-1 IPF composition with decades of NHLBI P01 support—license diligence on OCF-203.
Brown-origin US11717528B2—sublicense or asset path via Ocean / Elkurt corporate stack.
Open dossierInjectable human ECM morsels for HF and IPF—Slater-seeded Brown spinout.
Slater $375K + BBII—large-animal PoP before Heartseed-class Series A.
Open dossierDual-path NICU play—IAIP biologic plus rapid LFIA on active SBIR stack.
~$3.7M+ active SBIR—physician-founder equity; Series A $5–10M band vs Inotrem/MeMed.
Open dossierBlock dendritic recruitment to AD brain—$30M Series A with RI Hub IND grant.
MITI-101 mAb post–Series A—co-invest or extension with Slater/RightHill in syndicate.
Open dossierOne blood draw, full transcriptome—faster pathogen ID than culture, with host splicing biomarkers.
RIH-owned deep RNA platform + NIGMS R35 + Brown RNA Center—physician-founder spinout before national blood-RNA Dx scale-up.
DARPA intelligent spinal interface—SCI rehab IDE distinct from cortical BCI.
DARPA $6.3M + NCT04302259—medtech strategic or SPV vs wireless neurograins.
One-shot gene therapy at repair—faster, stronger tendon healing than surgery alone.
RIH-origin patents + ~$1.7M seed + RILSH LIFT for IND—physician-chairman Liu MD with pre-IND complete.
Open dossierASO switch for neural stem-cell quiescence—Brown Fallon/Webb science in a Slater-backed Providence newco.
NIA STTR + $1.5M pre-seed (Slater, Lifespan Vision)—formation capital before Big Pharma neurogenesis comparables.
Open dossierKIWI wireless micro-implant BCI—Providence HQ with BrainGate FTO diligence.
Nurosene partnership + strategic path—harvest Howard/ni2o USPTO vs Brown patents.
Open dossierHIF-pathway oncology with Welireg-scale commercial proof—harvest El-Deiry estate.
R01CA173453 + SMURF-Tx Providence—Slater seed after biomarker PoC.
Open dossierCOBRE-backed interoception pain DTx—spinout forming from Carney.
Kaia-class financing vs Pear Ch.11 payer lesson—SaMD path after pivotal pilot.
HiTIMED immune epigenetic deconvolution—Dartmouth EP pending, Brown collaborator.
R01 stack + EP4505463A1—pharma license model, not classic biotech VC.
Wearable ML for earlier pediatric sepsis recognition—validated in Bangladesh ICU cohort.
FIC R33TW012211 → US SaMD path; pairs with RIH RNA Dx stack.
URI PHLIP delivers cargo into acidic tissues—LNP and STING programs without classic endocytosis.
URI tech transfer → RI spinout or license; Engelman/Reshetnyak PHLIP science (PMID 24659971).
Salivary extracellular vesicles as a non-invasive Alzheimer's liquid biopsy.
RIH/Brown R01AG074284 supports analytical development; path to CLIA LDT then spinout.
BX-912 program for pulmonary hypertension—RIH PCT with multi-center inventor team.
Preclinical PH models → IND-enabling; benchmark against 2024 PAH biologic approval.
RIH diagnostic panel for pulmonary arterial hypertension and sudden cardiac death risk.
Mature US20180094317 family; retrospective → prospective validation.
RIH platform for nucleic acid delivery across the blood–brain barrier.
Qian Chen (NanoDe peer) leads BBB nucleic delivery PCT; partner or license path.
Motile injectable cell therapy to accelerate meniscus and connective-tissue repair.
NIAMS R01AR080726 + R21AR077326 (Jayasuriya); large-animal next gate.
Biomimetic ECM reconstitution for musculoskeletal joint repair.
Field-of-use diligence vs XM Therapeutics before Slater-scale spinout.
Enhancer RNA–targeted approach for primary brain tumors.
Tapinos-led RIH/Brown program; glioma model efficacy before neuro-onc seed.
RIH therapeutic approach to lower lipoprotein(a)—cardiovascular metabolic niche.
Differentiate vs Phase 3 siRNA/antisense leaders; Song lab R01HL159204 anchors cardio lipid biology.